Embody Review

Embody at a glance: a price-led entry point with one genuinely unusual product

Embody — the storefront actually trades as "Em" at joinem.co, run by a Delaware company called Modern Metabolic Medicine, Inc. — is built around one clear pitch: get people onto a compounded GLP-1 for as little money as possible up front. Its semaglutide program opens at $99 for the first month, which is among the lowest entry rates we track in the compounded segment (the category median sits around $169). If your main barrier to starting is the first invoice, Embody is designed to remove it. But the headline number is a teaser, and the most interesting thing about this provider isn't actually the price — it's a chewable. Embody is one of the very few telehealth brands offering a compounded oral tirzepatide gum for people who don't want to inject.

How the pricing really works — and where the catch is

Read the promo carefully, because the gap between month one and month two is large. Compounded semaglutide starts at $99 for the first month; tirzepatide injections start a bit higher. After that, refills lock in at $299 per month for either drug. So the $99 figure is an introduction, not your ongoing cost — budget for $299 as the real monthly number. To Embody's credit, it states this plainly: the company's own FAQ says refills are "locked in at $299" with no contract, so there's no surprise auto-escalation beyond that single step-up. Medication, the clinician consult, and shipping are all bundled into that monthly price, so $299 is close to all-in rather than a base fee you stack add-ons onto.

• First month: $99 for compounded semaglutide; a low-three-figure intro rate for compounded tirzepatide injection.
• Ongoing refills: $299 per month for either injectable, no contract.
• Oral tirzepatide gum: a separate flat monthly rate in the low-to-mid three hundreds, with no first-month teaser.
• Included: medication, the clinician consult, and free expedited shipping — no separate membership fee.

The oral tirzepatide gum — the real differentiator

Most compounded GLP-1 providers are interchangeable: same two molecules, same vials, slightly different prices. Embody's oral tirzepatide gum is the rare thing that genuinely sets it apart. For needle-averse patients, an alternative delivery route is a real draw, and almost nobody else offers it. That said, be clear-eyed about what you're buying. A compounded oral tirzepatide has no FDA-approved counterpart, and how much of an oral GLP-1 dose your body actually absorbs is still an open question in the clinical literature — oral bioavailability for these peptides is genuinely debated, not settled. The gum is priced higher than the ongoing injectable rate, so you're paying a premium for a convenience format whose absorption is less established than a standard injection. It's a reasonable option if injecting is a dealbreaker for you; it's not the choice to make purely to save money or to chase the strongest result.

Medications and how they're dispensed

Everything here is compounded — there is no FDA-approved brand-name option. You will not get Ozempic, Wegovy, Zepbound, or Mounjaro through Embody; you get compounded semaglutide and tirzepatide formulated by a compounding pharmacy, plus the oral gum. That's normal for this price tier, but it matters for two reasons. First, compounded drugs aren't reviewed by the FDA the way brand products are. Second, Embody does not publicly name its compounding pharmacy partners, so you can't independently check the source the way you can with providers that disclose a named, accredited pharmacy. If pharmacy transparency is important to you, that opacity is a real limitation — it's the main reason our confidence in this listing is medium rather than high.

Trust, safety, and medical oversight

On oversight, Embody does the basics right. Medical leadership sits with Dr. Alan Viglione, MD, who is board-certified in internal medicine, and the program includes unlimited 24/7 clinician messaging for dose questions and side-effect support — useful in the first weeks when nausea and titration questions are most common. We found no FDA warning letters against Embody or Modern Metabolic Medicine as of our last verification, and the company discloses the GLP-1 class black-box warning prominently on its safety page rather than burying it. The honest caveat is the one above: the unnamed pharmacy source. Good physician leadership and clear safety disclosure are genuine positives, but they sit alongside limited supply-chain transparency, and we'd weight both when you decide. You can see how we balance these signals in our scoring methodology.

Who should choose Embody — and who should skip it

Embody fits you if cost-to-start is the thing standing between you and your first dose, if you want coverage that works in all 50 states with no insurance hoops, or if you specifically want to try an oral, non-injectable tirzepatide and are comfortable with a less-established format. The bundled medication, consult, and shipping keep it simple. Skip it if you want a name-brand GLP-1, if you need to know exactly which accredited pharmacy is making your medication before you'll commit, or if you'll feel misled when month two jumps to $299 — in which case compare the ongoing $299 rate against other providers rather than the $99 hook, because plenty of competitors are cheaper on the number that actually recurs.

Bottom line

Embody is a sensibly run, all-50-states compounded GLP-1 provider with credible physician oversight and one feature almost no one else has: an oral tirzepatide gum. Its $99 first month is a real way to lower the cost of starting, but the $299 ongoing price is what you should plan around, and the undisclosed pharmacy source keeps it out of the top transparency tier. Choose it for the cheap start or the needle-free option — just go in judging it on the recurring rate, not the teaser.